Distinct effects of complement and of NLRP3- and non-NLRP3 inflammasomes for choroidal neovascularization

NLRP3 inflammasome activation and complement-mediated inflammation have been implicated in promoting choroidal neovascularization (CNV) in age-related macular degeneration (AMD), but central questions regarding their contributions to AMD pathogenesis remain unanswered. Key open questions are (1) whe...

Full description

Saved in:
Bibliographic Details
Published ineLife Vol. 9
Main Authors Malsy, Jakob, Alvarado, Andrea C, Lamontagne, Joseph O, Strittmatter, Karin, Marneros, Alexander G
Format Journal Article
LanguageEnglish
Published England eLife Science Publications, Ltd 11.12.2020
eLife Sciences Publications, Ltd
eLife Sciences Publications Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:NLRP3 inflammasome activation and complement-mediated inflammation have been implicated in promoting choroidal neovascularization (CNV) in age-related macular degeneration (AMD), but central questions regarding their contributions to AMD pathogenesis remain unanswered. Key open questions are (1) whether NLRP3 inflammasome activation mainly in retinal pigment epithelium (RPE) or rather in non-RPE cells promotes CNV, (2) whether inflammasome activation in CNV occurs via NLRP3 or also through NLRP3-independent mechanisms, and (3) whether complement activation induces inflammasome activation in CNV. Here we show in a neovascular AMD mouse model that NLRP3 inflammasome activation in non-RPE cells but not in RPE cells promotes CNV. We demonstrate that both NLRP3-dependent and NLRP3-independent inflammasome activation mechanisms induce CNV. Finally, we find that complement and inflammasomes promote CNV through independent mechanisms. Our findings uncover an unexpected role of non-NLRP3 inflammasomes for CNV and suggest that combination therapies targeting inflammasomes and complement may offer synergistic benefits to inhibit CNV.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:2050-084X
2050-084X
DOI:10.7554/eLife.60194